Successful Sorafenib Treatment for Metastatic Renal Cell Carcinoma in a Case with Chronic Renal Failure

European Urology

Volumn 55, Issue 4, 2009, Pages 986-988

  Ruppin, Sebastian ^a   Protzel, Chris ^b   Klebingat, Klaus Jürgen ^a   Hakenberg, Oliver W ^b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Renal cell cancer; Renal failure

Indexed keywords

ALPHA INTERFERON; SORAFENIB;

AGED; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CHRONIC KIDNEY FAILURE; DIARRHEA; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG METASTASIS; MALE; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY NEOPLASMS; MALE; PYRIDINES;

EID: 60249091896     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.10.027     Document Type: Short Survey

References (7)

1. Patard J.-J., Rioux-Leclercq N., and Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 49 (2006) 633-643
2. Ravaud A., Wallerand H., Culine S., et al. Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol 54 (2008) 315-325
3. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
4. Escudier B., Eisen T., Stadler W.M., et al. TARGET Study Group: sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
5. Maisonneuve P., Agodoa L., Gellert R., et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354 (1999) 93-99
6. Lathia C., Lettieri J., Cihon F., Gallentine M., Radtke M., and Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 57 (2006) 685-692
7. Bhojani N., Jeldres C., Patard J.-J., et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53 (2008) 917-930